Table 2.
IgG antibodies and microbiological surveillance of patients with candidemia and Candida colonization
| |
Anti-Eno |
Anti-Fba1 |
||||||
|---|---|---|---|---|---|---|---|---|
|
Microorganism |
Candidemia |
Candida colonization |
Candidemia |
Candida colonization |
||||
| n | No. (%) positive | n | No. (%) positive | n | No. (%) positive | n | No. (%) positive | |
|
C. albicans |
25 |
21 (84.0) |
37 |
1 (2.7) |
25 |
23 (92.0) |
37 |
2 (5.4) |
|
C. tropicalis |
20 |
9 (45.0) |
7 |
1 (14.3) |
20 |
16 (80.0) |
7 |
2 (28.6) |
|
C. parapsilosis |
21 |
18 (85.7) |
1 |
0 (0) |
21 |
19 (90.5) |
1 |
0 (0) |
|
C. glabrata |
10 |
7 (70.0) |
3 |
2 (66.7) |
10 |
8 (80.0) |
3 |
1 (33.3) |
|
C.guilliermondii |
5 |
3 (60.0) |
— |
— |
5 |
5 (100.0) |
— |
— |
|
Candida spp. |
20 |
15 (75.0) |
2 |
1 (50.0) |
20 |
17 (85.0) |
2 |
0 (0) |
| Total | 101 | 73 (72.3)a | 50 | 5 (10.0) | 101 | 88 (87.1)b | 50 | 5 (10.0) |
X2a =51.94, P < 0.01; X2b =84.1, P < 0.01, when compared with the control (patients with candida colonization).